Pharmaceutical Investment Oversight and Accountability Act

This bill would require the Federal Trade Commission (FTC), working with the Treasury Department's Committee on Foreign Investment in the United States, to send a yearly report on foreign investment in the U.S. drug industry. The first report would be due within one year after the bill becomes law. The report would look at the drug supply chain, reliance on foreign manufacturing, effects of foreign investment on U.S. capacity to make drugs and drug ingredients, and foreign investment in DNA sequencing and storage. It would also list and describe federal reviews of foreign deals in these areas over the past 10 fiscal years. The FTC would post an unclassified summary of the report on its public website.

Full text and official record on Congress.gov

Sponsors

• Elizabeth Warren Democrat sponsor
• 2 cosponsors